EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Adjuvant Imatinib for Patients Resected for GIST : A Quality Assurance Study

Hajer Mohammad iD, Hanne Krogh Rose, Philip Blach Rossen, Ninna Aggerholm Pedersen

Cancer Medicine · 2026-05 · 15 (5)

DOI: 10.1002/cam4.71912 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 12.05.2026. Verfasst von Hajer Mohammad und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Imatinib Mesylate, Gastrointestinal Stromal Tumors, Neoplasm Recurrence, Local, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The administration of adjuvant Imatinib for three years is a standard care of treatment in Denmark and indicated after resection of GIST with high and intermediate risk of recurrence. There are no reported real‐world data on the safety of the treatment and the impact of adjusted treatment for the outcome of recurrence.

Methods

This is a retrospective study quality assuring the tolerability of three‐year treatment and amplify this duration effective to reduce the risk of relapse. The primary endpoint is to assure the safety of the treatment. Secondary endpoints are recurrence‐free‐survival and overall survival.

Results

From January 1st 2019 to 31st December 2023, 225 patients were collected, 71 were referred to adjuvant treatment. Further six patients were excluded due to a short follow‐up, ending with 65 eligible patients for inclusion. In a median follow‐up of three years, a total of 60% were reduced in dosage due to toxicity, majority continuing with 400 mg and 17% were interrupted due to toxicity. There was no significant difference in the group of recurrence and treatment reduction or interruption. A total of 23% had relapse with a median time from diagnosis to recurrence of 4.5 years.

Interpretation

Three years of adjuvant Imatinib is a tolerable duration with no significant rate of recurrence among patients who were reduced or interrupted in treatment due to toxicity. This study reports a significance between high mitotic index and the relapse rate and a relation between recurrence and tumor site, tumor size and KIT exon 9 mutation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Imatinib MesylateGastrointestinal Stromal TumorsNeoplasm Recurrence, LocalProtein Kinase InhibitorsGastrointestinal NeoplasmsAntineoplastic AgentsHumansFemaleRetrospective StudiesChemotherapy, AdjuvantMaleMiddle AgedAgedQuality Assurance, Health CareAdultAged, 80 and overDenmark

Stichwörter der Autor:innen

adjuvant treatmentgastrointestinal stromal tumorimatinibquality assurance

Substanzen

Imatinib MesylateProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

ORCID-Profile: Hajer Mohammad

Zitieren

APA

Mohammad, H., Rose, H. K., Rossen, P. B., & Aggerholm Pedersen, N. (2026). Adjuvant Imatinib for Patients Resected for GIST : A Quality Assurance Study. Cancer Medicine, 15(5). https://doi.org/10.1002/cam4.71912

Vancouver

Mohammad H, Rose HK, Rossen PB, Aggerholm Pedersen N. Adjuvant Imatinib for Patients Resected for GIST : A Quality Assurance Study. Cancer Medicine. 2026;15(5). doi:10.1002/cam4.71912

BibTeX
@article{Mohammad2026,
  author = {Mohammad, Hajer and Rose, Hanne Krogh and Rossen, Philip Blach and Aggerholm Pedersen, Ninna},
  title = {Adjuvant Imatinib for Patients Resected for GIST : A Quality Assurance Study},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.1002/cam4.71912}
}
Kostenlos starten →